Glucagon-like peptide-1 receptor agonists improve outcomes in individuals with type 2 diabetes with and without heart failure
Authors:
- 10 October 2024
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 418, 132611
Abstract
No abstract availableKeywords
Funding Information
- Clinical Science Research and Development
This publication has 31 references indexed in Scilit:
- Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of AmericaJournal of Cardiac Failure, 2023
- Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 DiabetesJACC: Clinical Electrophysiology, 2023
- Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT TrialsJournal of Cardiac Failure, 2023
- Prognostic Interplay Between COVID-19 and Heart Failure With Reduced Ejection FractionJournal of Cardiac Failure, 2022
- Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor AgonistsJACC, 2020
- Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart FailureJAMA Cardiology, 2020
- Medical Therapy for Heart Failure With Reduced Ejection FractionJACC, 2018
- Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2018
- European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-Year Follow-Up Outcomes and Differences Across RegionsEuropean Journal of Heart Failure, 2016
- The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary ApplicationCurrent Epidemiology Reports, 2015